Tussilagone Suppresses Angiogenesis by Inhibiting the VEGFR2 Signaling Pathway

Tussilagone (TSL) is a sesquiterpenoid isolated from , which has been used as a traditional medicine for the treatment of asthma and bronchitis. It also takes part in the anti-inflammatory and antioxidant effects, but its role in angiogenesis is unknown. Angiogenesis is a cancer feature that is esse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in pharmacology 2019-07, Vol.10, p.764-764
Hauptverfasser: Li, Jia, Peng, Jiangtong, Zhao, Shengnan, Zhong, Yi, Wang, Yilong, Hu, Ji, Zhang, Chao, Cheng, Min, Xia, Geqing, Hu, Yu, Huang, Kai, Wang, Yan, Liang, Minglu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tussilagone (TSL) is a sesquiterpenoid isolated from , which has been used as a traditional medicine for the treatment of asthma and bronchitis. It also takes part in the anti-inflammatory and antioxidant effects, but its role in angiogenesis is unknown. Angiogenesis is a cancer feature that is essential for supplying oxygen and nutrients to all proliferating tumor cells. Here, we demonstrated that TSL significantly inhibited the proliferation, migration, invasion, and tube formation of primary human umbilical vascular endothelial cell (HUVEC) . Also, TSL inhibited vascular endothelial growth factor (VEGF)-induced angiogenesis revealed by Matrigel plug assay . At present, we observed that TSL inhibited the activity of VEGFR2 signal pathway induced by VEGF. These findings suggested that TSL may serve as a potential therapeutic target in the angiogenesis.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.00764